La cadena de opciones muestra datos clave de las opciones de acciones de Contineum Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Contineum Therapeutics..

Contineum Therapeutics (NASDAQ:CTNM) Bolsa, Cadena de Opciones

Contineum Therapeutics

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics Inc

CHINA TREASURES NEW MATLS by CHINA TREASURES NEW MATLS GROUP LTD

China Treasures New Materials Group Ltd

On Thursday, Palisade Bio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock is trading higher with a strong session volume of 26.97 million, compared to an average volume of 107.68k as per data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
Palisade Bio priced an underwritten public offering for gross proceeds of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42466940/palisade-bio-announces-pricing-of-5-million-underwritten-public-offering-priced-at-market-under-na" rel="noreferrer noopener">approximately $5 million</a>.
The offering comprises 158,000 Class A Units and 3.12 million Class B Units. The price per Class A Unit is $1.525, and the price per Class B Unit is $1.5249.
The Common Warrants will have an exercise price of $1.40 per share, will be exercisable at issuance, and will have a term expiring five years from issuance.
The company will use the net proceeds primarily to fund the Phase 1 trial of PALI-2108, pre-clinical studies, research and development, and working capital.
Last week, Palisade Bio revealed preliminary results from its first three single ascending dose (SAD) cohorts in its ongoing Phase 1 human study for PALI-2108 <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42289096/palisade-bio-announces-preliminary-data-from-phase-1-clinical-study-of-pali-2108-for-the-treatment" rel="noreferrer noopener">for Ulcerative Colitis</a>.
Preliminary results appear to indicate that PALI-2108 was safe and well tolerated in the first three cohorts (n=24; 6:2 active to placebo) at 15mg, 50mg, and 150mg, with no treatment-related dose reductions, no Treatment-Related Adverse Events (TRAEs), no Serious Adverse Events (SAEs), and no treatment-related lab abnormalities in any subject.
Preliminary pharmacokinetics data from the first cohorts demonstrated delayed release of the PDE4 inhibitor active suggesting PALI-2108 is performing as designed with colonic bioactivation.
Based on the findings with this preliminary safety data, the company is advancing toward its planned crossover study to evaluate the effects of food on pharmacokinetics, followed by multiple ascending dose (MAD) cohorts and, finally, a multiple-dose cohort of patients with Ulcerative Colitis.
The company is on track to report topline data from this study in the first half of 2025.
As of September 30, the company had cash and cash equivalents of $8.0 million. The company believes it has sufficient cash to fund its planned operations through the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41900382/palisade-bio-reports-third-quarter-2024-financial-results-and-outlines-key-accomplishments-and-nex" rel="noreferrer noopener">first quarter of 2025</a>.
Price Action: PALI stock is trading 51.5% higher at $2.12 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/asset-sales/24/12/42459145/3d-systems-agrees-to-sell-geomagic-portfolio-for-123-million-ai-and-3d-printing-take-center-stage" target="_blank" rel="noreferrer noopener">3D Systems Agrees To Sell Geomagic Portfolio For $123 Million, AI And 3D Printing Take Center Stage</a></li>
</ul>

Biotech

News

Health Care

Financing

Offerings

Movers

Trading Ideas

General

PALI

What's Going On With Palisade Bio Stock On Thursday?

WIIM

TORO

Toro shares are trading higher after the company announced it entered into a Share Purchase Agreement with MPC Münchmeyer Petersen & Co. GmbH for the acquisition of 26,116,378 shares representing 74.09% of the shares of the Frankfurt-listed investment and asset manager MPC Münchmeyer Petersen Capital AG.

Stifel analyst Patrick Ho reiterates Camtek (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>) with a Buy and maintains $105 price target.

Price Target

Reiteration

Analyst Ratings

CAMT

Stifel Reiterates Buy on Camtek, Maintains $105 Price Target

HC Wainwright &amp; Co. analyst Oren Livnat maintains Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) with a Buy and raises the price target from $6 to $7.5.

TRVI

HC Wainwright & Co. Maintains Buy on Trevi Therapeutics, Raises Price Target to $7.5

Loop Capital analyst Alton Stump maintains Dave &amp; Buster's Enter (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) with a Buy and lowers the price target from $59 to $45.

PLAY

Loop Capital Maintains Buy on Dave & Buster's Enter, Lowers Price Target to $45

BTIG analyst Julian Harrison downgrades Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) from Buy to Neutral.

Downgrades

KROS

BTIG Downgrades Keros Therapeutics to Neutral

Loop Capital analyst Anthony Chukumba maintains Tractor Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) with a Hold and raises the price target from $265 to $290.

TSCO

Loop Capital Maintains Hold on Tractor Supply, Raises Price Target to $290

IPOs

TTAN

ServiceTitan Shares Open For Trade At $101/Share; IPO Priced At $71/Share On 8.8M Shares

Loop Capital analyst Laura Champine maintains Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) with a Hold and lowers the price target from $35 to $30.

MTCH

Loop Capital Maintains Hold on Match Group, Lowers Price Target to $30

Streaming Destination for HBO, Warner Bros. Pictures, the DC Universe, A24, ID and More Now Available to All Spectrum TV Select Customers at No Extra Cost
STAMFORD, Conn. and NEW YORK, Dec. 12, 2024 /PRNewswire/ -- Spectrum and Warner Bros. Discovery Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) today announced that WBD's premium streaming service Max is now available to all of Spectrum's TV Select video customers at no additional cost, as part of the two companies' new distribution agreement. Spectrum TV Select customers will receive Max With Ads, which retails for $9.99 per month and includes must-see entertainment from brands such as HBO, Warner Bros., Max Originals, DC, Harry Potter, as well as iconic shows like "Friends" and "The Big Bang Theory."

CHTR

Spectrum And Warner Bros. Discovery Announce WBD's Streaming Service Max Is Now Available To All Of Spectrum's TV Select Video Customers At No Additional Cost, As Part Of The Two Companies' New Distribution Agreement

BTIG analyst Ryan Zimmerman maintains Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) with a Buy and raises the price target from $87 to $91.

GMED

BTIG Maintains Buy on Globus Medical, Raises Price Target to $91

European pharma service provider Lonza Group Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LZAGY#OTC">LZAGY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LZAGF#OTC">LZAGF</a>) announced plans to exit its Capsules &amp; Health Ingredients (CHI) business.
Full implementation is expected by second quarter of 2025.
The decision coincides with the company&#8217;s strategy to focus on contract development and manufacturing organization (CDMO). Lonza expects EBITDA margins exceeding 30% for its CDMO segment beyond 2025.
William Blair writes that the decision to divest its CHI business and reorganize the CDMO business &#8220;rids Lonza of the main drag&#8221; and &#8220;creates a much cleaner and more compelling pure-play CDMO story.&#8221;
The new structure aims to simplify operations by transitioning from three divisions and nine business units to three integrated business platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities.
The Integrated Biologics platform will consolidate Mammalian and Drug Product Services, while Advanced Synthesis merges hybrid chemistry and biology solutions, incorporating the Small Molecules division and Bioconjugates.
Specialized Modalities will be focused on cell and gene therapies, mRNA, and microbial solutions.
2024 and Beyond: Growth Outlook
<ul>
<li>Lonza maintained its 2024 guidance of flat constant exchange rate (CER) sales growth and a CORE EBITDA margin between 27% and 29%, with CDMO performance offsetting softness in the CHI segment.</li>
<li>For 2025, Lonza projects CER sales growth approaching 20%, supported by the acquisition of the Vacaville site and organic growth in the low teens.</li>
<li>Beyond 2025, the company anticipates low-teen percentage CER sales growth.</li>
<li>For CHI, Lonza expects modest growth and a gradual return to higher margins post-2025.</li>
<li>Lonza reaffirmed its commitment to a dividend policy with a payout ratio of 35-45%.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42465586/gevo-and-lg-chem-push-ahead-on-eto-commercialization-for-sustainable-aviation-and-bio-propylene-markets" target="_blank" rel="noreferrer noopener">Gevo And LG Chem Double Down On Ethanol-To-Olefins Tech: Details</a></li>
</ul>

Analyst Color

LZAGF

LZAGY

Swiss Contract Service Provider Lonza Exits Capsules Business To Focus On Drug Development

Editor&#8217;s note: the headline has been updated to more accurately reflect BlackRock&#8217;s recommended portfolio allocation.
The world's largest asset manager, BlackRock Inc. (NASDAQ; BLK), suggests that Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) could hold a place in <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42143299/bitcoin-etfs-will-see-hundreds-of-billions-in-inflows-analyst-predicts">multi-asset portfolios</a>, albeit within a narrow range.
Quoting a report from the BlackRock Investment Institute, Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-12-12/blackrock-says-up-to-2-bitcoin-allocation-is-reasonable-range?embedded-checkout=true">reported</a> that allocating 1% to 2% of a portfolio to Bitcoin would produce a risk profile comparable to investing in the &#8220;Magnificent Seven&#8221; technology stocks within a traditional 60/40 portfolio of equities and bonds.
Exceeding the 2% threshold, however, could disproportionately increase the portfolio&#8217;s risk.
The report provides guidance for investors seeking to balance exposure to Bitcoin, especially as the cryptocurrency continues to trade at record highs above $100,000. 
President-elect Donald Trump&#8216;s <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42422705/donald-trump-would-welcome-150000-bitcoin-early-in-presidency-its-another-stock-market-for-him">crypto-friendly policies</a>, coupled with his pro-crypto leadership appointments, have contributed to a surge in <a href="https://www.benzinga.com/news/events/24/12/42437939/bitcoin-etfs-spark-institutional-interest-the-doors-have-been-blown-off-superstate-ceo-says">Bitcoin exchange-traded funds</a> (ETFs), including BlackRock's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>).
These developments have fueled billions in inflows and intensified interest in integrating Bitcoin into mainstream investment strategies.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42460507/hacker-exploits-dogecoin-vulnerability-crashes-69-of-nodes-but-doge-still-spikes-1-8">Hacker Exploits Dogecoin Vulnerability, Crashes 69% Of Nodes—But DOGE Still Spikes 1.8%</a>
"Even though Bitcoin's correlation with other assets is relatively low, its inherent volatility makes its impact on total portfolio risk similar to that of highly concentrated tech stocks," stated Samara Cohen, BlackRock&#8217;s Chief Investment Officer of ETF and Index Investments, in the paper. 
A small allocation to Bitcoin could add diversification, whereas an overweight position in high-risk tech equities might exacerbate concentration risks, the report noted.
Despite Bitcoin&#8217;s 140% rise this year, its path to historic highs has been marked by extreme volatility, with historical drawdowns ranging between 70% and 80%, the paper highlighted. 
However, the introduction of <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42393396/record-week-bitcoin-etfs-net-25-billion-in-inflows-ethereum-etfs-took-in-12-billion">U.S. spot Bitcoin ETFs</a> earlier this year has played a pivotal role in its rally.
Since their January launch, these ETFs have attracted over $113 billion in assets, with nearly <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42380475/bitcoin-etfs-have-outstripped-satoshi-nakamotos-holdings">$10 billion flowing in</a> since November, according to Bloomberg data.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42457774/donald-trump-reportedly-tapping-brian-quintenz-as-head-of-commodity-futures-trading-commission">Donald Trump Reportedly Tapping Brian Quintenz As Head Of Commodity Futures Trading Commission</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

IBIT

BlackRock: 'Reasonable Range' Of Bitcoin Allocation In Multi-Asset Portfolios Is Between 1-2% (UPDATED)

LBGJ

Li Bang International Shares Resume Trading

Realty Income's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) short percent of float has risen 21.18% since its last report. The company recently reported that it has 18.72 million shares sold short, which is 2.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.92 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Realty Income Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734025521_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Realty Income has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Realty Income's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Realty Income's peer group average for short interest as a percentage of float is 5.16%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(O) - Analyzing Realty Income's Short Interest

Elevance Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) short percent of float has fallen 9.63% since its last report. The company recently reported that it has 2.82 million shares sold short, which is 1.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.66 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Elevance Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734025516_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Elevance Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Elevance Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Elevance Health's peer group average for short interest as a percentage of float is 5.71%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Peering Into Elevance Health's Recent Short Interest

<a href="https://www.benzinga.com/personal-finance/24/10/41213012/dave-ramseys-bold-plan-to-fight-inflation-could-his-radical-approach-help-you-keep-more-cash-in-">Dave Ramsey</a>, renowned financial guru, proud father of three grown kids and grandfather of seven, doesn't mince words when it comes to life lessons.
In a blog post, Ramsey delivered a powerful message about parenting, warning against the dangers of shielding kids from the consequences of their actions. His reflections, sparked by an adorable exchange with his four-year-old granddaughter, offers humor and hard truths.
Don't Miss:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a></li>
<li><a href="https://www.benzinga.com/money/cd-valet-growth">CD Popularity Soars: Over 50 Million Americans Embrace Safe Savings with 5–10% Annual Growth</a></li>
</ul>
While vacationing with his family at their lake house, Ramsey asked his granddaughter where her cousin was. The little girl's response – "He is in the house with his dad" – set up a moment of parenting gold. When Ramsey inquired further, she replied, "My cousin is experiencing consequences."&nbsp;
Intrigued, Ramsey asked, "Have you experienced consequences?" Her answer – "Oh yes, Pappa Dave and it's not fun, but I learned a lot" – left him both amused and proud. It also highlighted a simple yet powerful truth: great parenting raises kids who understand responsibility.
Ramsey argues that many parents today are failing their children by protecting them from failure and discomfort. He's not alone in this belief. Parenting experts like Andy Andrews have long said the goal isn't to raise great kids but to raise kids who will become great adults.&nbsp;
See Also: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Last Chance to get 4,000 of its pre-IPO shares for just $0.26/share!</a>
According to Ramsey, "enabling" or "helicopter parenting" holds today's youth back – and the numbers prove it.
A report by The Hill found that nearly half of parents are still paying their adult children's bills, shelling out an average of $1,442 per month. Shockingly, 25% of <a href="https://www.benzinga.com/real-estate/24/09/41093903/millennials-are-house-rich-how-one-generation-doubled-their-wealth">millennials </a>rely on their parents to cover housing costs.&nbsp;
Ramsey quickly clarifies that temporary support isn&#8217;t the issue in the face of genuine hardship – like illness or divorce. But when a safety net becomes a hammock, it robs young adults of dignity, resilience and motivation.
Ramsey uses a vivid metaphor to drive his point home. Eagles build their nests with sharp thorns and soften them with down to protect their young. When the eaglets are ready to fly, the parents remove the down, making the nest uncomfortable.&nbsp;
This discomfort pushes the young eagles to spread their wings and soar. In contrast, Ramsey laments that today's parents are creating a generation of adults stuck in "nests," unwilling to leave.
Trending: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
The consequences are staggering. Economist Nicholas Eberstadt's book Men Without Work reveals that 7.2 million able-bodied men, ages 25 to 54, are neither working nor looking for work.
Supported by parents, partners or the government, many in this group are plagued by depression, addiction and even suicide. Ramsey says this tragic reality highlights how society has failed to teach these individuals the value of struggle and hard work.
In his bestseller The Comfort Crisis, Michael Easter argues that modern life has become so easy that we've lost our ability to tackle tough challenges. Ramsey agrees, urging parents to embrace – and teach – the benefits of hard things. Struggle builds character and character builds hope, he says.
Ramsey acknowledges that many young people are hardworking and mission-driven, particularly at his company, Ramsey Solutions. But for those who lack grit, he points the finger at overprotective parenting. "When we remove consequences, we clip their wings," he says. "And instead of soaring like eagles, they become turkeys."
Read Next:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
</ul>

Personal Finance

Dave Ramsey Warns Against 'Hammock Parenting'—'7.2 Million Able-Bodied Men Aren't Even Looking For Work And It's Not Their Fault'

Veeva Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) short percent of float has fallen 16.87% since its last report. The company recently reported that it has 1.97 million shares sold short, which is 1.33% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.66 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Veeva Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734025511_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Veeva Systems has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Veeva Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Veeva Systems's peer group average for short interest as a percentage of float is 6.45%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

VEEV

(VEEV) - Analyzing Veeva Systems's Short Interest

Chardan Capital analyst Geulah Livshits maintains Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) with a Buy and maintains $212 price target.

KRYS

Chardan Capital Maintains Buy on Krystal Biotech, Maintains $212 Price Target

Bernstein analyst Zhihan Ma maintains Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) with a Outperform and raises the price target from $301 to $304.

Bernstein Maintains Outperform on Lowe's Companies, Raises Price Target to $304

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Buy rating on Contineum Therapeutics, Inc. Class A (CTNM – Research Repor...

Morgan Stanley Sticks to Its Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM)

Contineum Therapeutics GAAP EPS of -$0.39

IPO Roundup: FrontView REIT, StandardAero and more

Joel Beatty, an analyst from Robert W. Baird, has initiated a new Buy rating on Contineum Therapeutics, Inc. Class A (CTNM). Joel Beatty's rating i...

Promising Prospects and Strong Financials Bolster Buy Rating for Contineum Therapeutics

Baird initiated coverage of Contineum (CTNM) with an Outperform rating and $32 price target Contineum is an early clinical stage biotech company de...

Contineum initiated with an Outperform at Baird

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Contineum Therapeutics, Inc. Class A (CTNM – Research Report) today and set a price...

Stifel Nicolaus Reaffirms Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)

"The third quarter of 2024 was focused on clinical execution for our lead assets PIPE-307 and PIPE-791, where we have multiple potential opportunit...

Contineum reports Q3 EPS (40c), consensus (41c)

Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from Stifel Nicolaus

Contineum (CTNM) announced authorization of its investigational new drug, or IND, application from FDA for PIPE-791 for the treatment of chronic pa...

Contineum announces FDA authorization for PIPE-791

Contineum Therapeutics, Inc. Class A ( ($CTNM) ) has released its Q3 earnings. Here is a breakdown of the information Contineum Therapeutics, Inc. ...

Contineum Therapeutics: Q3 2024 Financial Overview

ACTHF

APUS

BIOA

CHARU

CTNM

CUPR

FBGL

GRDN

HUHU

MAMO

PTLE

SARO

SNYRD

SUNH

TLIH

TMGX

ZBAO

Press Releases

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics to Attend Upcoming Investor Conferences

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Comments

Contineum Therapeutics

Contineum Therapeutics (CTNM) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL